Harpoon Therapeutics Strengthens Leadership Team
December 26 2023 - 7:30AM
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage
immunotherapy company developing novel T cell engagers, today
announced the appointment of James Bucher, J.D. as Chief Legal
Officer, and the promotion of Wendy Chang, to Chief People Officer.
Mr. Bucher and Ms. Chang are part of the executive management team
and report directly to the Chief Executive Officer.
“I am delighted to welcome Jim to the Harpoon leadership team
and announce Wendy’s promotion. I look forward to benefiting from
Jim’s extensive experience as we continue to advance the clinical
development of our T cell engagers and execute toward multiple
milestones in the next year,” said Julie Eastland, Harpoon
Therapeutics’ President and Chief Executive Officer. “Wendy has
made an invaluable impact on our organization in a short period.
Her promotion to Chief People Officer is a testament to her ability
to lead people strategy aligned with Harpoon’s strong culture and
our patient-centric mission.”
Mr. Bucher is a proven leader with over thirty years of legal
expertise, including over ten years dedicated to senior roles in
life science companies. Most recently, he served as Executive Vice
President, General Counsel, and Head of Human Resources at Eliem
Therapeutics. Mr. Bucher also served as Executive Vice President
and General Counsel for Alder Biopharmaceuticals, held a senior
legal position at Exelixis, consulted life sciences companies, and
was a partner at Shearman & Sterling LLP. In his current role
at Harpoon, Mr. Bucher is tasked with leading all legal aspects of
the organization, including corporate governance, intellectual
property, and compliance functions. Mr. Bucher received his J.D.
with distinction from Emory University School of Law and his B.A.
from Colgate University.
Ms. Chang joined Harpoon in 2022 as Senior Vice President of
Human Resources, bringing more than twenty years of human resources
experience in life sciences. Ms. Chang’s promotion to the role of
Chief People Officer demonstrates her valuable contributions to the
Company during her tenure, along with the organization's commitment
to its employees, corporate culture, and the future growth and
development of its team. Ms. Chang has an extensive background
in aligning talent with organizations’ overall vision and
direction. Before joining Harpoon, she was Head of People and
Culture at IDbyDNA; before that, she served as Vice President,
Human Resources at Gilead Sciences. Ms. Chang earned a B.S. in
accounting and business/management from the University of
California, Riverside, and completed the Global Fellow of Talent
Management program at The Wharton School of the University of
Pennsylvania.
Inducement Award under NASDAQ Listing Rule
5635(c)(4)In connection with Mr. Bucher’s appointment,
Harpoon Therapeutics granted him an inducement non-qualified stock
option to purchase an aggregate of 110,000 shares of Harpoon’s
common stock.
The stock option grant has an exercise price per share equal to
$11.30, Harpoon’s closing trading price on Nasdaq on the grant date
of December 21, 2023, and will vest over 4 years, with 1/4 of the
underlying shares vesting on the one-year anniversary of the grant
date and 1/36th of the underlying shares vesting monthly thereafter
over 36 months, subject to Mr. Bucher’s continued service
relationship with Harpoon through the applicable vesting dates.
The independent directors of Harpoon’s Board of Directors
approved the award as an inducement material to Mr. Bucher’s
employment in accordance with Nasdaq Listing Rule 5635(c)(4).
About Harpoon Therapeutics Harpoon
Therapeutics is a clinical-stage immunotherapy company
developing a novel class of T cell engagers designed to harness the
power of the body’s immune system to treat patients suffering from
cancer and other diseases. T cell engagers are engineered proteins
that direct a patient’s own T cells to kill target cells that
express specific proteins, or antigens, carried by the target
cells. Using its proprietary Tri-specific T cell Activating
Construct (TriTAC®) platform, Harpoon is developing a pipeline of
novel TriTACs initially focused on the treatment of solid
tumors and hematologic malignancies. Harpoon has also developed a
proprietary ProTriTAC™ platform, which applies a prodrug
concept to its TriTAC platform to create a therapeutic T cell
engager that remains inactive until it reaches the tumor. Harpoon’s
third proprietary technology platform, extended release TriTAC-XR,
is designed to mitigate cytokine release syndrome. For additional
information about Harpoon Therapeutics, please visit
www.harpoontx.com.
Forward-Looking Statements This press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Words such as
“continue,” “will” and similar expressions (as well as other words
or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements.
These forward-looking statements are based on Harpoon Therapeutics’
expectations and assumptions as of the date of this press release.
Each of these forward-looking statements involves risks and
uncertainties that could cause Harpoon Therapeutics’ clinical
development programs, future results or performance to differ
significantly from those expressed or implied by the
forward-looking statements. Forward-looking statements contained in
this press release include, but are not limited to, statements
relating to the effects of advancing Harpoon Therapeutics’
platforms, the company’s future business growth and partnerships,
expectations regarding strengthening the company’s business team
and other statements that are not historical fact. These and other
factors that may cause Harpoon Therapeutics’ actual results to
differ from those expressed or implied in the forward-looking
statements in this press release are discussed in Harpoon
Therapeutics’ filings with the U.S. Securities and Exchange
Commission. Except as required by law, Harpoon
Therapeutics assumes no obligation to update any
forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
Contact:Ana KaporHarpoon
Therapeuticsinvestors@harpoontx.com
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From Apr 2024 to May 2024
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From May 2023 to May 2024